Brief: Spruce Biosciences Completes Target Enrollment of CAHmelia-203 Study
18/10/2023 13:26
Oct 18 (Reuters) - Spruce Biosciences Inc SPRB.O :
* SPRUCE BIOSCIENCES COMPLETES TARGET ENROLLMENT OF
CAHMELIA-203
STUDY IN ADULT CLASSIC CONGENITAL ADRENAL HYPERPLASIA
* SPRUCE BIOSCIENCES INC - CAHMELIA-203 TOPLINE RESULTS
ANTICIPATED IN Q1 OF 2024
* SPRUCE BIOSCIENCES INC - CAHMELIA-204 COMPLETION OF
ENROLLMENT
ANTICIPATED IN EARLY Q1 OF 2024
* SPRUCE BIOSCIENCES INC - FINAL ENROLLMENT IN CAHMELIA-203
TO
EXCEED TARGET DUE TO SUBSTANTIAL PATIENT INTEREST
Source text for Eikon: ID:nBw6BwPjla
Further company coverage: SPRB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spruce Biosciences
See all newsSpruce Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Spruce Biosciences Q2 net loss widens on higher expenses
Spruce Biosciences, Inc. expected to post a loss of $5.80 a share - Earnings Preview
Brief: Spruce Biosciences Appoints Adrian Quartel, M.D., Ffpm, As Chief Medical Officer
Brief: Spruce Biosciences Announces Data Presentation At The 18Th International MPS Symposium